Anti Neurofascin 186 Antibody Positivity C5676732
An antibody targeting nerve structure proteins that can cause nerve inflammation, leading to weakness or sensory changes.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Acute motor weakness
Areflexia
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Sensory deficits
(neurologic)Pain
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Acute immunotherapy
High-dose intravenous immunoglobulin or plasma exchange for acute antibody-mediated nerve damage, particularly important in Guillain-Barré syndrome variants.
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Corticosteroid therapy
Pulse methylprednisolone or oral prednisone to suppress inflammatory response against neurofascin-186 antigens.
Additional treatment options
Plasmapheresis
Therapeutic plasma exchange to physically remove pathogenic antibodies from circulation, often used in acute presentations.
procedureNeurological rehabilitation
Comprehensive rehabilitation including gait training, strength exercises, and functional mobility work to recover from acute neurological deficits.
physical_therapyRespiratory and cardiac monitoring
Vital capacity monitoring and cardiac assessment due to risk of autonomic dysfunction and respiratory compromise in neuropathies affecting these systems.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Anti Neurofascin 186 Antibody Positivity C5676732?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Ng DT, Hiew FL, Shahrizaila N. Anti-neurofascin 186 antibodies in autoimmune neuropathies: Pathophysiology and clinical implications. J Neurol Neurosurg Psychiatry. 2022;93(5):512-520.
Devaux JJ, Miura Y, Fukami Y, et al. Antibodies to neurofascin-186 in chronic inflammatory demyelinating polyneuropathy. Neurology. 2016;86(9):800-807.
Querol L, Nogales-Gadea G, Rojas-Garcia R, et al. Neurofascin 186 antibodies in subacute autoimmune demyelinating polyneuropathies. Brain. 2014;137(Pt 6):1628-1638.
Van den Bergh PY, Hadden RD, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol. 2010;17(3):356-363.
Medication Comparisons
Compare medications used to treat Anti Neurofascin 186 Antibody Positivity C5676732. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy